MTOR and head and neck squamous cell carcinoma: We also showed that mTOR inhibitors (mTORi) exert potent antitumor activity in multiple experimental HNSCC model systems (reviewed in11) and in a recent Phase 2 clinical trial in HNSCC patients12.